Form 4: Rhythm Pharmaceuticals CTO Executes Pre-Planned Option Exercise and Share Sale

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold an equivalent number of common shares on July 9, 2025, under a Rule 10b5-1 plan, maintaining his beneficial ownership.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), completed a series of transactions on July 9, 2025.
• Exercised stock options to acquire 7,969 shares of common stock at an exercise price of $6.80 per share.
• Immediately sold 3,984 shares of common stock at a weighted average price of $75.5649 per share, with prices ranging from $75.12 to $75.92.
• Additionally sold 3,985 shares of common stock at a price of $80.00 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on August 8, 2024.
• Following these transactions, Joseph Shulman's direct beneficial ownership of common stock remained at 8,509 shares.
• The stock options exercised were granted on February 9, 2022, and vest in 16 substantially equal installments upon completion of each three full months of successive service.

Sentiment

Score: 5

Explanation: Neutral. The document reports routine insider transactions (option exercise and sale) which are common. The sales were pre-planned under a 10b5-1 plan, which is a positive for transparency, but the act of selling shares by an insider can sometimes be perceived negatively, even if it's for personal financial management. The net effect on beneficial ownership of common stock was zero shares from these specific transactions (exercised 7,969, sold 7,969), maintaining the insider's overall holding at 8,509 shares.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned sales and enhancing transparency, which can mitigate concerns about opportunistic insider trading.
• The significant difference between the option exercise price of $6.80 and the sale prices of $75.5649 and $80.00 indicates a substantial personal gain for the insider from their equity compensation.

Negatives

• An insider selling a notable number of shares (7,969 shares) could be perceived negatively by some market participants, even when conducted under a pre-planned trading arrangement.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider trading activities.

Industry Context

This Form 4 filing details routine insider transactions (option exercise and sale) for a biotechnology company. Such transactions are common for executives managing their equity compensation and personal finances. The use of a Rule 10b5-1 plan is standard practice to mitigate insider trading concerns. The specific prices reflect the market value of Rhythm Pharmaceuticals' stock at the time of the transactions, which can be influenced by broader biotech sector trends, clinical trial progress, and regulatory developments.

Comparison to Industry Standards

• Insider transactions like these are standard practice across industries, particularly in high-growth sectors like biotechnology where executive compensation often includes significant equity components.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, similar to how executives at companies like Moderna or Pfizer might manage their stock holdings.
• The specific prices and volumes are unique to Rhythm Pharmaceuticals and its stock performance, but the mechanism of exercise and sale is comparable to those seen in other publicly traded companies.

Stakeholder Impact

• Shareholders: May observe an insider selling shares, which could be interpreted in various ways, though the pre-planned nature via a 10b5-1 plan mitigates some concerns. The insider's beneficial ownership of common stock remained unchanged by these specific transactions.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Beneficial Ownership, Chief Technical Officer, Biotechnology